PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION TREATED WITH ABI-009, NAB-SIROLIMUS, AN MTOR INHIBITOR: INTERIM RESULTS FROM A PHASE 1 CLINICAL TRIAL

mTOR activation is implicated in the proliferative aspect of PAH. ABI-009, albumin-bound nanoparticle sirolimus, has anti-proliferative activity and high lung accumulation, and is being explored as a novel treatment approach in patients (pts) with severe PAH. This phase 1 study investigates the